 Esperion Therapeutics continues to report lackluster growth with their NEXLETOL and NEXLIZET products. As a result, the share price continues to hit fresh all-time-lows with little-to-no signs of a reversal. The companys transformative long-term growth plan is starting to show some success with a boost in revenue and a reduction in OpEx. The market doesnt appear to be impressed. 